Intuitive Surgical, Inc. (ISRG)
ISRG's International Growth Outpaces US With 35% Procedure Volume
Intuitive Surgical sees international procedures jump 23% in 2025, now 35% of total, outpacing U.S. growth and reshaping its long-term expansion strategy.
Is It Worth Investing in Intuitive Surgical (ISRG) Based on Wall Street's Bullish Views?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Intuitive Surgical, Inc. (ISRG) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Intuitive Surgical (ISRG). This makes it worthwhile to examine what the stock has in store.
Will ISRG's R&D Focus Following Solid Earnings Growth Drive Demand?
Intuitive Surgical balances 22% EPS growth with heavier 2026 R&D and expansion spending, betting near-term margin pressure will fuel long-term demand.
Should You Buy ISRG Stock Despite a 13% Fall in Three Months?
Shares of Intuitive Surgical ISRG have declined 13.5% over the past three months, despite continued strong procedure growth and robust adoption of the da Vinci 5 system in fourth-quarter 2025. Over the same period, the company's shares lagged the industry's 8% decline and significantly underperformed the S&P 500 Index, which rose 2.8%.
Intuitive Surgical, Inc. (ISRG) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Intuitive Surgical (ISRG) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Can Intuitive Surgical Sustain Robust Top-line Growth in 2026?
ISRG posts 20.5% revenue growth in 2025, driven by higher procedure volumes and da Vinci 5 adoption, and guides for 13-15% procedure growth in 2026.
Intuitive Surgical: Buy The January Selloff
Intuitive Surgical remains a compelling long-term buy despite recent share price weakness and mixed Q4 results. Da Vinci 5 adoption is robust, with 74% YoY system placement growth and expanding FDA-approved use cases. 2026 guidance is soft, with procedure growth expected to slow to 13–15%, but headwinds are seen as temporary.
Is Intuitive Surgical (ISRG) a Buy as Wall Street Analysts Look Optimistic?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Bull of the Day: Intuitive Surgical (ISRG)
Never bet against the da Vinci surgical system.
ISRG's da Vinci Gets FDA Nod for Advanced Cardiac Procedures
Intuitive Surgical wins FDA 510(k) clearance for the da Vinci 5 system in select cardiac procedures to expand minimally invasive heart surgery.
China Remains Competitive: Can ISRG Defend Share Amid Local Rivals?
ISRG faces slower China tenders, local favoritism and pricing pressure, even as clinicians prefer da Vinci and management flags 2026 competition.
